Cargando…

Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)

BACKGROUND: The objective of the study was to evaluate the efficacy and safety of upadacitinib over 84 weeks in Japanese patients with active rheumatoid arthritis (RA) and an inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs. METHODS: All patients completing a 12-w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kameda, Hideto, Takeuchi, Tsutomu, Yamaoka, Kunihiro, Oribe, Motohiro, Kawano, Mitsuhiro, Yokoyama, Masayuki, Pangan, Aileen L., Konishi, Yuko, Meerwein, Sebastian, Tanaka, Yoshiya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789301/ https://www.ncbi.nlm.nih.gov/pubmed/33407801 http://dx.doi.org/10.1186/s13075-020-02387-6

Ejemplares similares

Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study
por: Kameda, Hideto, et al.
Publicado: (2020)

The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan
por: Yamaoka, Kunihiro, et al.
Publicado: (2021)

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
por: Strand, Vibeke, et al.
Publicado: (2019)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Sunrise : a play in four acts /
por: Yu, Tsao 1957-
Publicado: (1978)

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial
por: van Vollenhoven, Ronald, et al.
Publicado: (2020)

The Esplanade des particules at sunrise
por: Brice, Maximilien
Publicado: (2023)

COVID-19: thoughts at sunrise
por: Gasbarrini, Giovanni
Publicado: (2020)

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
por: Mease, Philip J, et al.
Publicado: (2021)

SUNRISE-DI study. The daily sunrise is easier to predict than the benefit of adjuvant treatment in colon cancer
por: Carmona-Bayonas, A., et al.
Publicado: (2021)

Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis
por: Nader, Ahmed, et al.
Publicado: (2019)

Antes del amanecer = Before sunrise
Publicado: (1995)

Sunrise deploys mobile network for CERN
Publicado: (2004)

International Study of Movement Behaviors in the Early Years (SUNRISE): Results from SUNRISE Sweden’s Pilot and COVID-19 Study
por: Delisle Nyström, Christine, et al.
Publicado: (2020)

Sunrise, Chatterton Falls, Quetico Provincial Park
por: Blacklock, Craig, et al.
Publicado: (2015)

Chitosan-based mucosal adjuvants: Sunrise on the ocean
por: Xia, Yufei, et al.
Publicado: (2015)

Overview of biotherapy in rheumatoid arthritis (RA)
por: Takeuchi, Tsutomu, et al.
Publicado: (2012)

What is the future of CCR5 antagonists in rheumatoid arthritis?
por: Takeuchi, Tsutomu, et al.
Publicado: (2012)

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
por: McInnes, Iain B, et al.
Publicado: (2021)

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
por: Strand, Vibeke, et al.
Publicado: (2019)

Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
por: Strand, Vibeke, et al.
Publicado: (2020)

Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study
por: Kubo, Satoshi, et al.
Publicado: (2023)

Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy
por: Zeng, Xiaofeng, et al.
Publicado: (2021)

Vitamin D in midlife: The sunrise vitamin in the sunset of life
por: Kaushal, Manila Jain, et al.
Publicado: (2012)

Boost in radiotherapy: external beam sunset, brachytherapy sunrise
por: Maciejewski, Boguslaw
Publicado: (2009)

Circadian immunity, sunrise time and the seasonality of respiratory infections
por: Mo, Ziyi, et al.
Publicado: (2021)

Immune sunrise: from the immunome to the cancer immune landscape
por: Bindea, Gabriela, et al.
Publicado: (2022)

Microsaccades mediate perceptual alternations in Monet’s “Impression, sunrise”
por: Alexander, Robert G., et al.
Publicado: (2021)

Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison
por: Huizinga, Thomas, et al.
Publicado: (2023)

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study
por: Mease, Philip J., et al.
Publicado: (2021)

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases
por: Kameda, Hideto, et al.
Publicado: (2007)

Upadacitinib for rheumatoid arthritis
Publicado: (2020)

Analytic treatment of the two loop equal mass sunrise graph
por: Laporta, S., et al.
Publicado: (2004)

Sunrise for new opportunities at ‘Carol Davila’ University of Medicine and Pharmacy
por: Popa, F
Publicado: (2010)

Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study
por: Takahashi, Chihiro, et al.
Publicado: (2017)

Distinct features distinguishing IgG4-related disease from multicentric Castleman’s disease
por: Sasaki, Takanori, et al.
Publicado: (2017)

MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
por: Charles-Schoeman, Christina, et al.
Publicado: (2023)

Upadacitinib for the treatment of psoriatic arthritis
por: Fonseca, Diogo, et al.
Publicado: (2023)

IgG4-Related Disease without Overexpression of IgG4: Pathogenesis Implications
por: Nishina, Naoshi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_e566q708ugtakgf7qtm0ev9nt2